Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Silo Pharma ( (SILO) ) has shared an announcement.
On July 8, 2025, Silo Pharma, Inc. entered into an Agreement with the University of Maryland, Baltimore, terminating a previous Master License Agreement from February 12, 2021. This new Agreement grants Silo Pharma an exclusive evaluation license and an option to negotiate a commercial license for intellectual property related to central nervous system-homing peptides, aimed at treating neuroinflammatory diseases globally. The Agreement, effective until March 31, 2026, allows Silo Pharma to potentially secure a sublicensable, royalty-bearing license, enhancing its strategic positioning in the biotechnology sector.
More about Silo Pharma
Silo Pharma, Inc. operates in the biotechnology industry, focusing on developing innovative therapeutics for neuroinflammatory diseases. The company leverages intellectual property related to central nervous system-homing peptides to advance its research and development efforts.
Average Trading Volume: 1,012,291
Technical Sentiment Signal: Sell
Current Market Cap: $4.41M
Find detailed analytics on SILO stock on TipRanks’ Stock Analysis page.